GlassScriptPhysician profile
Sherry A Hall
NPI 1508249327
$1,824.08
in general payments reported to CMS, 2019-2025
19 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $196 · 2023: $217 · 2024: $726 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $663.85 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $270.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $153.32 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $121.26 | 2022-2024 | Injectafer |
| Abbvie INC. | $92.91 | 2023-2024 | |
| Amgen INC. | $81.59 | 2022-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.05 | 2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $58.44 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $47.94 | 2022-2023 | |
| Glaxosmithkline, LLC. | $43.08 | 2023-2024 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $36.76 | 2023-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $34.33 | 2023-2025 | |
| Lilly USA, LLC | $24.66 | 2024 | Jardiance |
| Biogen, INC. | $24.37 | 2024 | Spinraza |
| Exact Sciences Corporation | $20.62 | 2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $19.96 | 2025 | Thinprep 2000 Processor, Aptima |
| Rhythm Pharmaceuticals, INC. | $19.22 | 2025 | Imcivree |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2023 | Nuedexta |
| Radius Health, INC. | $14.97 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.